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Abstract
In this article we summarize several recent major developments in human immunodeficiency virus treatment, 
prevention, outcome, and social policy change. Updated international guidelines endorse more aggressive treatment 
strategies and safer antiretroviral drugs. New antiretroviral options are being tested. Important lessons were learned in 
the areas of human immunodeficiency virus vaccines and microbicide gels from clinical studies, and additional trials in 
prevention, especially pre-exposure prophylaxis, are nearing completion. Insight into the role of the virus in the 
pathogenesis of diseases traditionally thought to be unrelated to acquired immunodeficiency syndrome has become a 
driving force for earlier and universal therapy. Lastly, we review important achievements of and future challenges 
facing China as she steps into her eighth year of the National Free Antiretroviral Treatment Program.
Introduction
Antiretroviral therapy (ART) has evolved from mono-
therapy with zidovudine (AZT) to the use of combination
nucleoside reverse transcriptase inhibitors (NRTIs), to
triple therapy with highly active antiretroviral therapy
(HAART), to today's numerous combinations drawn
from 6 classes and 32 drugs, including fixed dose formu-
lations, approved by the United States (US) Food and
Drug Administration (FDA) [1]. Treatment goals have
also progressed from achieving viral suppression to regi-
men simplification, to long term durability, and to the
present paradigm of treatment as prevention. In the past
2 decades, HIV mortality has dramatically decreased
reflecting the success of ART [2,3]. New drugs with fewer
side effects and lower pill burden have made long term
viral suppression a reality. As death rates related to
acquired immunodeficiency syndrome (AIDS) continue
to decline in patients receiving treatment, attention has
shifted to what have heretofore been considered non-
AIDS-related deaths. In this paper we will review some of
the most important recent advances in HIV medicine and
comment on their significance for the future of HIV
treatment and care in China.
HIV Treatment
New Strategies
The US Department of Health and Human Services
(DHHS) [4] and the World Health Organization (WHO)
[5] both released new guidelines in 2009. The overall
treatment strategies include earlier initiation of ART,
individualized treatment based on comorbidities, and
regimen optimization to minimize toxicity and potential
for drug resistance.
The new US DHHS guidelines for ART initiation have
expanded to include all patients with pregnancy, HIV-
associated nephropathy, and hepatitis B virus (HBV)
coinfection requiring treatment for HBV, regardless of
CD4 count, and in all patients with CD4 <350 cells/mm3.
In addition, ART is now recommended for all patients
with CD4 between 350 and 500 cells/mm3. As for patients
with CD4 > 500 cells/mm3, the panel of experts is evenly
split between favoring ART initiation and considering it
optional. These changes stem from mounting evidence
that earlier ART initiation, even before any significant
CD4 drop and immune deficiency symptoms, translates
to better immune recovery, better tolerance for side
effects, smaller risk for TB reactivation, and reduced HIV
and TB transmission on a public health level [6-10]. It
should be noted, however, that the "moderate level of evi-
dence" for these benefits comes primarily from observa-
tional studies conducted in the US and Europe [9,10] and
to a large extent reflects reduced cardiovascular compli-
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1750 subjects with HIV infection who have been random-
ized to receive ART at CD4 >350 cells/mm3 or when CD4
declines to 250 cells/mm3 [11]. The Strategic Timing of
Antiretroviral Treatment(START) trial, another interna-
tional multi-center randomized study, is underway to
compare immediate commencement of ART at CD4 >500
cells/mm3 to deferral of ART until CD4 declines below
350 cells/mm3 in terms of morbidity and mortality [12].
These trials will provide stronger evidence than observa-
tional studies for the benefits of early therapy in asymp-
tomatic patients with high CD4 counts.
Preferred regimens for ART-naïve patients have also
been revised. They now include the integrase inhibitor
raltegravir (Isentress), recently approved by the US Food
and Drug Administration (FDA) for ART-naïve patients,
in combination with the NRTIs tenofovir (TDF) and
emtricitabine (FTC) [13]. Three other preferred options
include: TDF/FTC in combination with efavirenz (EFV),
and with the boosted protease inhibitors (PIs) darunavir/
ritonavir (DRV/r) and atazanavir/ritonavir (ATV/r). Due
to its effects on cholesterol and the gastrointestinal (GI)
system, the boosted PI lopinavir/ritonavir (LPV/r) is now
an alternate choice except for pregnant women. These
regimens are not without side-effects, as EFV causes CNS
symptoms and ATV raises bilirubin levels in select
patients. Owing to concerns regarding its efficacy in set-
tings of high baseline viral load (VL) and damage on the
cardiovascular system, abacavir (ABC) is now an alterna-
tive regimen in the US guidelines but was kept as a pre-
ferred NRTI backbone in the recently updated European
guidelines [14]. Due to conflicting data [15-18], there is
not yet a consensus on this issue.
In contrast to the US DHHS guidelines, the WHO rec-
ommendations target resource-limited countries and are
more conservative. In the most recent WHO draft guide-
lines [19], immunologic criterion for initiating ART in
adults and adolescents was raised from a baseline CD4 of
200 to 350 cells/mm3, regardless of symptoms. However,
these guidelines have not been widely adapted in part
because of limited drug supplies. To reduce rates of
mother to child transmission and improve child survival,
treatment to prevent mother to child transmission start-
ing at 14 instead of 28 weeks and continuing through
breastfeeding was added as an option. Although ART can
be delivered safely without routine monitoring of hema-
tology and biochemistry in resource-limited settings
based on the Development of AntiRetroviral Therapy in
Africa (DART) study [20], expanded laboratory monitor-
ing of CD4 and VL was advised to guide better the switch
to second line therapies.
The WHO now urges replacing the NRTI stavudine
(d4T) with AZT or TDF. d4T is inexpensive and widely
available but causes mitochondrial toxicity that can lead
to sometimes permanent peripheral neuropathy and lip-
odystrophy. Its phase-out will be difficult given that a
large proportion of patients on ART in developing coun-
tries are reliant on d4T-containing first line regimens, but
the new WHO recommendation may prove to be more
cost-effective in the long run [21].
New Drugs
In addition to updated guidelines, several new antiretro-
viral (ARV) drugs were approved by the US FDA this past
year for treatment-naive HIV patients. Raltegravir, as pre-
viously mentioned, was approved based on results from
the STARTMRK trial, a double blind controlled study
comparing raltegravir to EFV in combination with TDF/
FTC [13,22]. Viral suppression at 48 weeks and rate of
resistance mutation were comparable, and raltegravir was
better tolerated with fewer central nervous system side
effects [23].
The use of the CCR5 antagonist maraviroc (Selzentry)
was also expanded by the FDA to include ART-naïve
patients with CCR5-tropic HIV-1 virus [24]. Maraviroc
prevents HIV entry by blocking CCR5 coreceptors. It
works well in treatment-naïve patients, most of whom
carry CCR5-tropic viruses only. Highly sensitive tropism
testing is necessary prior to use since subjects with mixed
or CXCR4-tropic HIV-1 infection did not respond well to
maraviroc in phase-2 study. The Maraviroc versus Efa-
virenz Regimens as Initial Therapy (MERIT) trial [25]
showed that compared to EFV, maraviroc was slightly less
effective at achieving viral suppression below 50 copies/
ml in patients with higher baseline VL but was more
effective at increasing CD4 counts in ART-naïve patients.
Those on maraviroc also reported better lipid profiles.
Discontinuation rates were similar among the two
groups, though more patients on maraviroc discontinued
due to treatment failure, while more patients on EFV dis-
continued for adverse events. A post hoc analysis of
patients screened by a tropism assay with enhanced sen-
sitivity yielded similar results except for fewer discontin-
uations due to lack of efficacy and a better overall
response rate in the maraviroc group, particularly for
patients with high baseline VL [26]. Of note, although a
previous CCR5-antagonist was suspected of increasing
cancer risk in early studies, fewer cases of malignancies
were observed in the maraviroc group, but whether or
not this difference was statistically significant was not
clear.
The development of 2 new pharmaco-enhancing
agents, GS9350 [27] by Gilead and SPI-452 [28] by
Sequoia pharmaceuticals, represents major steps toward
identifying alternatives to ritonavir. Ritonavir is a PI that
does not affect HIV VL at the booster dose (100 or 200
mg per day) but alters the metabolism of other PIs
through inhibition of the cytochrome P450 3A (CYP3A)
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increases the maximal concentration achieved by other
PIs, allowing more convenient dosing and higher barrier
to resistance. However, ritonavir is associated with side
effects including dyslipidemia, diabetes, and GI dysfunc-
tion [30]. As it is the only validated booster drug used
with PIs, Abbott which owns the patent currently has a
monopoly in the market. A heat stable formulation is cur-
rently accessible in the US and may become more widely
available later in 2010, but in many places ritonavir still
requires cold-chain storage. Both of the new boosting
agents successfully completed phase-2 trials. SPI-452 and
GS9350 were both shown to enhance safely and effec-
tively the level of PIs [28,31,32]. In addition, when a fixed
dose quad pill containing GS9350, elvitegravir (integrase
inhibitor), TDF, and FTC was compared with fixed dose
EFV, FTC, and TDF (Atripla), the quad pill had a lower
rate of adverse events [32].
HIV Prevention
The Hope for an HIV Vaccine
Results from the phase-3 Thai vaccine trial using a com-
bination of ALVAC, a recombinant canarypox vector vac-
cine, and AIDSVAX, a recombinant glycoprotein-120
subunit vaccine, were released late 2009. Although the
two protocol specified analyses (intention-to-treat and
per-protocol) only showed a trend toward significance,
the modified intention-to-treat analysis excluding 7 sub-
jects who were determined to be HIV-infected at study
entry showed a 31% (95% confidence interval 1.1-51.2)
reduction in the risk of HIV infection [33-35], making
this the first HIV vaccine to have a statistically significant
effect. The vaccine did not affect VL or CD4 counts in
participants who became infected, and no serious safety
concerns were identified. The greatest protective effect
was during the first year and in heterosexual participants
at low or medium risk. Although the mechanisms by
which protection was provided are unknown, the authors
concluded that this vaccine may be valuable in a commu-
nity setting with largely heterosexual risk.
Prevention with Microbicide Gel
Disappointing news came from the vaginal microbicide
gel PRO 2000 trial [36,37] conducted by the Microbicides
Development Programme (MDP) from 2005 to 2009 in
9385 women in 4 African countries with high HIV preva-
lence rates. Women were randomly assigned to receive
the PRO 2000 gel (0.5% dose) or placebo, along with free
condoms. Despite good adherence and tolerability, no
significant difference in infection rates was observed (4.5/
100 person-year with the PRO 2000 gel versus 4.3/100
person-year with placebo). A similar but smaller study of
3099 women from 6 sites in Africa and 1 in the US
(HPTN035) sponsored by the US National Institutes of
Health (NIH) earlier in 2009 was more promising, show-
ing a 30% reduction in HIV infections [38]. This result,
however, was just short of the pre-defined criterion for
statistical significance. To date, no microbicide has been
proven effective in a clinical trial. A TDF-containing
microbicide gel is currently being tested as pre-exposure
prophylaxis [39]. The CAPRISA-004, a phase-2b study
conducted in 980 sexually active women in South Africa
compares the efficacy of 1% TDF gel to placebo in pre-
venting HIV infection when used 12 hours before and
after intercourse [40,41], and results will be available July
2010.
Oral ART as Pre-exposure Prophylaxis
As newer drugs with less toxicity have made earlier ART
administration feasible, they are also being considered for
pre-exposure prophylaxis (PrEP) to prevent HIV infec-
tion. TDF was effective in preventing Simian Immunode-
ficiency Virus (SIV) infection in the macaque model [42],
and to date use as PrEP in human trials has revealed no
serious safety concerns [43]. Complex mathematical
models have shown the potential for oral PrEP to reduce
significantly HIV transmission, although its utility and
effectiveness have not yet been proven by randomized tri-
als and may be undermined by cost [44], behavioral disin-
hibition [45], and more frequent transmitted drug
resistance [46]. A PrEP trial with TDF/FTC is expected to
be completed in late 2010. The iPrEX study, a phase-3
randomized controlled trial, evaluates the efficacy and
safety of TDF/FTC (Truvada) among MSM at risk for
HIV infection at 11 sites in 5 countries [40].
The Vaginal and Oral Interventions to Control the Epi-
demic (VOICE) study, a large double blind placebo con-
trolled trial supported by the NIH [39], is underway to
test a daily regimen of TDF gel, TDF tablets, or Truvada
tablets in up to 5,000 women at risk for HIV infection in
four African countries. This innovative study directly
compares a microbicide gel with oral tablets and is the
first to test a gel that will be applied once daily rather than
shortly before sexual intercourse. The safety, efficacy, and
acceptability of these approaches will be evaluated.
Women comprise of more than half of all people living
with HIV, and the majority are infected through hetero-
sexual transmission [47]. If proven effective, this form of
PrEP would be vital in circumstances where it is difficult
for women to refuse sex or negotiate condom use.
Prevention with Early ART
HIV transmission is strongly correlated to the concentra-
tion of virus in blood (VL), and this is usually reflected in
genital secretions [48]. ART significantly reduces HIV
transmissibility by reducing VL, which is the basis for
treating HIV-infected pregnant women [49], infected
partners of sero-discordant heterosexual couples and
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sions [50,51].
Universal HIV testing and treatment has also been pro-
posed as a method to control the spread of HIV [52].
Using data from South Africa in a mathematical model,
Granich et al predicted that yearly universal voluntary
HIV testing with ART provided to all persons testing pos-
itive will reduce annual global HIV incidence by 95% to
below one per 1000 population per year within 10 years.
Within 5 years, the present endemic phase, where most
adults living with HIV are not on ART, will transition into
an elimination phase, in which most are on ART. Some
but not all studies comparing the cost of higher ART
demand to the savings from lower HIV transmission,
hospitalization, and improved quality of life suggest that
such a strategy can be cost-effective in the long run [53-
56].
Current evidence is insufficient to support a radical
policy change [57], as different models have shown vary-
ing degrees of public health benefit from ART depending
on the assumptions applied [58,59], and empirical data
are lacking. Future randomized trials and operational
research must address the potential for over-testing,
over-treatment, side effects, resistance, and risk behavior
changes. Ethical, human rights, political, and community
concerns must be weighed before such a policy can be
widely recommended. A delicate balance must be sought
especially in settings with scarce health care resources
and where patients rely on older generation ARV drugs,
which make optimal monitoring and treatment much
more challenging.
HIV Outcomes
Focus on Non-AIDS Related Deaths
With optimal ART, the life expectancy of persons living
with HIV in developed countries approaches that of HIV-
negative individuals [60]. As mentioned above, the latest
international guidelines emphasize the importance of
early therapy. It has also become clear that despite good
immune function, ongoing viral replication is injurious
and perhaps even accelerates the aging process, by caus-
ing persistent immune activation and inflammation [61].
This hypothesis is supported by studies showing that lev-
els of biomarkers for immune activation and inflamma-
tion, including C-reactive protein, interleukin-6, and D-
dimer, correlate with the use of ART and duration of HIV
infection [62,63]. Conditions traditionally considered
non-AIDS related, such as cardiovascular, renal, hepatic,
and neurologic diseases, as well as certain types of can-
cers, are becoming the dominant comorbidities in
patients on long term ART with CD4 >200cells/mm3 [64].
The cause of non-AIDS related complications is complex
and is in part due to adverse effects of long-term ARV use
[65]. Cumulative exposure to certain PIs such as lopina-
vir, indinavir, amprenavir, and fosamprenavir has been
associated with increased cardiovascular risk. Some
[16,18,65-69] but not all [70-73] observational studies
show that risk of myocardial infarction may be raised in
patients with current or recent exposure to ABC or
didanosine (ddI), although this has not been confirmed
by randomized trials [74]. Equally important, chronic
HIV replication may mediate changes in the endothelium
and clotting and inflammation pathways, causing end
organ damage [66,75-77]. As AIDS-related causes of
deaths are better controlled with improved ART in devel-
oping countries, non-AIDS related comorbidities will
become more notable. In the future, adjunct therapies to
regulate blood sugar, cholesterol, and other metabolic
disturbances will likely play a larger role in managing
non-AIDS related comorbidities in resource-limited set-
tings.
Social Change and Policy
Scientific advances sometimes cannot move society for-
ward without corresponding changes in policy. World-
wide, injection drug use is a major route of transmission
for both HIV and viral hepatitis due to needle sharing.
Needle exchange programs that provide clean needles to
injection drug users (IDUs) are controversial because
they are perceived as condoning the illegal and harmful
behavior. However, studies have shown that needle
exchange decreases transmission of blood borne patho-
gens and does not increase drug abuse [78]. The US
recently lifted a ban on the use of federal funds for needle
exchange in recognition of the merit of such programs.
HIV-positive individuals are a vulnerable population
not only concerning their health status but also because
of social discrimination and stigma. Currently, more than
60 countries have laws that restrict the entry, stay or resi-
dence of people living with HIV. In the early 1990's, at the
height of the epidemic when effective treatment was still
lacking, an entry and immigration policy was passed in
the US prohibiting HIV-positive individuals from enter-
ing the country. That ban was lifted effective January
2010, sending a clear message combating fear, stigma, and
discrimination against people living with HIV and AIDS.
As a result, the XIX International AIDS conference will
be held in Washington, DC in July 2012.
Implications for China
Since the scale-up of China's National Free Antiretroviral
Treatment Program (NFATP) in 2003, over 80,000
patients have been treated. Nine ARV drugs are currently
available, including 6 NRTIs (ABC, ddI, d4T, 3TC, TDF,
and AZT), 2 NNRTIs (EFV and NVP), and one boosted
PI (LVP/r). In addition, three drugs - raltegravir (inte-
grase inhibitor), darunavir (PI), and etravirine (NNRTI) -
are in the process of entering the Chinese market. China's
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ART initiation in all patients with CD4 count under 350
cells/mm3. The rapid scale-up of HIV treatment and care
has led to a dramatic decrease in HIV mortality from
roughly 27-30 deaths per 100 person-years before ART to
about 4-5 deaths per 100 person-years after ART [79,80].
However, major challenges remain in diversifying and
optimizing treatment options provided through the free
ART program. d4T is currently used as part of the first-
line regimen in close to half of all patients on ART in
China [79]. Its total replacement by AZT or TDF as rec-
ommended by the WHO will be challenging financially
and administratively. However, the long-term cost-effec-
tiveness of the new recommendations should be consid-
ered. Bender et al [21] showed that TDF- compared to
d4T-based first-line ART can be more durable due to bet-
ter efficacy and toxicity profiles. Additionally, fixed dose
combinations will be essential in reducing pill burden and
improving medication adherence [81,82], and newer
agents will be needed in special cases such as patients
with drug-resistance and IDUs on methadone treatment.
Cost is the major barrier to the introduction of new drugs
in China, but the NFATP is certainly moving toward the
expansion of ARV regimens.
As lower baseline CD4 count correlates to worse prog-
nosis, decreasing the treatment threshold and expanding
treatment coverage may be an urgent next step in China
to control both AIDS and non-AIDS related mortality
and morbidity. Most patients still present with late dis-
ease, and fewer than 1 in 3 HIV-positive individuals are
aware of their status [83]. At the end of August 2008, the
median baseline CD4 count of those enrolling into the
NFATP was only 118 cells/mm3 [79]. Resource limitation
is the biggest obstacle in implementing more aggressive
screening and treatment guidelines. A rise in the number
of patients eligible for ART will require increased ARV
supplies, improved laboratory monitoring capabilities,
and additional trained HIV care providers. The National
Center for AIDS/STD Control and Prevention (NCAIDS)
will raise funds to ensure sustainable supplies and con-
tinue to strengthen the physician education program ini-
tiated in 2002. With the expansion of ART coverage, first
line drug resistance and second line treatment availability
will become bigger concerns. ART resistance testing and
surveillance are currently being conducted and will
expand to nationwide coverage within the next 5 years.
NCAIDS is also considering greater cooperation with
nongovernmental organizations (NGOs) as a channel for
providing additional adherence counseling. As treated
patients live longer, long term ART-related side effects
like the above-mentioned mitochondrial toxicities will
require improved monitoring and management. Finally,
efforts are needed to reduce stigma, which prevents many
from receiving HIV testing and treatment. Infection with
HIV is often equated with being immoral - it is not
uncommon for HIV-positive individuals to be estranged
from their family, and the family from the community, all
driven by fear and shame. The Chinese government is
already taking steps to promote social tolerance by
expanding methadone maintenance treatment (MMT)
and needle and syringe programs (NSPs), removing the
requirement for viral hepatitis testing before school and
job entry, and lifting the entry ban on HIV-positive for-
eigner [84].
Substantial progress has been made in the area of harm
reduction, especially among IDUs. In 2006, the Ministry
of Health, Ministry of Public Security and the State Food
and Drug Administration (SFDA) issued the revised
"Opium Abusers Community-Based Drug Maintenance
Treatment Protocol," which expanded the MMT program
from pilot phase to general application. By the end of
2008, 558 MMT clinics in 23 provinces have served more
than 170,000 clients [85]. NSPs have expanded to a total
of 790 centers, about half of which were funded by the
government as of 2006 [86]. The US NIH also supports an
HIV prevention trial among HIV-negative IDUs in the
provinces of Guangxi and Xinjiang.
However, major hurdles remain among other risk
groups. Sexual transmission has become the fastest grow-
ing means of HIV transmission in China due to changing
sexual behavior and attitude since China opened up to
the outside world in the late 1970s [87]. Among new HIV
cases in China in 2007, close to 45% are infected through
heterosexual transmission, with the majority being trans-
mission between non-regular partners [88], including
female sex workers (FSW) and their clients. In one study,
60% of FSWs in China did not use condoms consistently
with their clients [88]. Considerable crossover exists
between risk groups, especially among commercial sex
workers and IDUs, creating a bridging effect of spreading
HIV from IDUs to the clients and regular sex partners of
FSWs [89]. While accounting for only about 2-5% of all
adult males [90], men who have sex with men (MSM)
represent an estimated 12% and rapidly growing propor-
tion of all HIV-positive persons in China [88,91]. The
Chinese MSM population is another important bridge for
the spread of HIV, as one-half report having sex with
women, and one-third being married. Research and inter-
vention among MSM have received increased funding
and attention from both the Chinese government and
international organizations [92,93]. Since most available
studies were conducted in large or medium-sized cities
among the well educated, additional research is needed
especially in rural areas and among military personnel,
prisoners, college students, and migrant workers [94]. For
both the FSW and MSM populations, more effective pre-
vention programs should be anchored in empirical evi-
dence-based research. Systematic surveillance and grass
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tive, oral or vaginal forms of PrEP would be useful for
sexual partners and uninfected members of these high
risk groups. Until then, continual efforts are needed in
sexual education, behavior modification, and improved
access to HIV testing and counselling.
Conclusion
We have summarized several recent major themes in
HIV/AIDS. We share in the disappointment from set-
backs, excitement of new successes, and hope in coming
advancements. Future directions in China as well as the
rest of the world will continue to focus on methods of
HIV prevention such as vaccine and microbicide devel-
opment, expanding HIV testing and treatment, discover-
ing and developing new ARV drugs, optimizing the ART
delivery system, and improving therapy for non-AIDS
related conditions and coinfections.
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